Literature DB >> 15277366

Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.

Yoshinori Hasegawa, Takeshi Sarashina, Maki Ando, Chiyoe Kitagawa, Atsuo Mori, Masao Yoneyama, Yuichi Ando, Kaoru Shimokata.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277366     DOI: 10.1373/clinchem.2004.034694

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  12 in total

1.  High-throughput single-base mismatch detection for genotyping of UDP-glucuronosyltransferase (UGT1A1) with probe capture assay coupled with modified allele-specific primer extension reaction (MASPER).

Authors:  Osamu Kisaki; Seiji Kato; Kohei Shinohara; Hisahide Hiura; Tomohiro Samori; Hiroshi Sato
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 2.  Patient profiling for treatment toxicity: potential use of clinical and genomic factors.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

3.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

4.  Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.

Authors:  Yutaka Negoro; Ryoichi Yano; Mari Yoshimura; Yoko Suehiro; Shinji Yamashita; Takaaki Kodawara; Kyohei Watanabe; Hitoshi Tsukamoto; Toshiaki Nakamura; Maiko Kadowaki; Miwa Morikawa; Yukihiro Umeda; Masaki Anzai; Tamotsu Ishizuka; Nobuyuki Goto
Journal:  Int J Clin Oncol       Date:  2018-10-17       Impact factor: 3.402

Review 5.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

6.  Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28.

Authors:  Ursula Ehmer; Tim O Lankisch; Thomas J Erichsen; Sandra Kalthoff; Nicole Freiberg; Michael Wehmeier; Michael P Manns; Christian P Strassburg
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

Review 7.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Authors:  Glenn E Palomaki; Linda A Bradley; Michael P Douglas; Katherine Kolor; W David Dotson
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

8.  Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.

Authors:  Takashi Shibata; Yosuke Minami; Ayako Mitsuma; Sachi Morita; Megumi Inada-Inoue; Tomoyo Oguri; Tomoya Shimokata; Mihoko Sugishita; Tomoki Naoe; Yuichi Ando
Journal:  Int J Clin Oncol       Date:  2013-04-23       Impact factor: 3.402

10.  Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.

Authors:  Ayako Tsuboya; Yutaro Kubota; Hiroo Ishida; Ryotaro Ohkuma; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Takuya Tsunoda; Yasutsuna Sasaki; Natsumi Matsumoto; Yusuke Kondo; Yukana Tomoda; Hiroyuki Kusuhara; Ken-Ichi Fujita
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-11       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.